Xencor, Inc., a clinical-stage biopharmaceutical company, reported a total revenue of $125.6 million for the fiscal year ending December 31, 2025, marking a 13.7% increase from $110.5 million in 2024. This growth was primarily driven by milestone payments and royalties from collaborations, particularly with Alexion Pharmaceuticals and Incyte Corporation. Notably, Xencor recognized $80.3 million in royalty revenue, a significant rise from $67.5 million in the previous year, reflecting the success of its partnered products, including Ultomiris, which is marketed by Alexion.
Despite the increase in revenue, Xencor's operating expenses also rose, totaling $303.1 million in 2025 compared to $288.9 million in 2024. Research and development expenses accounted for the majority of this increase, amounting to $239.4 million, up from $227.7 million the previous year. The company continues to invest heavily in its clinical pipeline, which includes several bispecific antibody candidates targeting cancer and autoimmune diseases. The net loss attributable to Xencor for 2025 was $91.9 million, a decrease from a loss of $232.6 million in 2024, indicating improved financial performance despite ongoing investments in R&D.
In terms of operational developments, Xencor has made significant strides in advancing its clinical programs. The company is currently conducting Phase 1 and Phase 2 studies for multiple XmAb drug candidates, including XmAb819 and XmAb541, which are designed to treat various cancers. The company also reported a total employee headcount of 260 as of December 31, 2025, with a focus on enhancing its research and development capabilities. Xencor's strategic partnerships with major pharmaceutical companies, including Amgen and Novartis, continue to play a crucial role in its growth strategy, providing both funding and expertise to advance its product candidates.
Looking ahead, Xencor anticipates that its existing cash reserves, totaling $610.8 million as of December 31, 2025, will be sufficient to fund operations through at least 2028. The company plans to continue its focus on advancing its clinical pipeline while exploring additional collaborations to enhance its development capabilities. However, Xencor acknowledges the inherent risks associated with biopharmaceutical development, including regulatory hurdles and market competition, which could impact its future financial performance and operational success.
About Xencor Inc
Xencor, Inc. is a biopharmaceutical company specializing in engineered antibody therapeutics for cancer and autoimmune diseases. Its core focus is on protein engineering to develop bispecific and multi-specific antibodies with enhanced properties. The company’s portfolio includes clinical-stage drug candidates and licensed medicines, leveraging proprietary Fc domain technologies to improve efficacy, half-life, and safety, primarily targeting oncology and inflammatory conditions worldwide.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.